ACM
YMAB

Aquatic Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Aquatic Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,520
Closed -$19.7K – 1678
2024
Q4 		$19.7K Buy
+2,520
New +$30.7K ﹤0.01% 1235
2024
Q2 		– Sell
-3,300
Closed -$53.7K – 1642
2024
Q1 		$53.7K Buy
+3,300
New +$44.5K ﹤0.01% 1018
2022
Q4 		– Sell
-7,500
Closed -$108K – 1888
2022
Q3 		$108K Buy
+7,500
New +$124K 0.01% 737
2022
Q2 		– Sell
-400
Closed -$5K – 1617
2022
Q1 		$5K Buy
+400
New +$4.11K 0.01% 837

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Aquatic Capital Management's YMAB Position: Q1 2025 in Review

Aquatic Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 2,520 shares — an estimated $19.7K sold.

Aquatic Capital Management first reported a position in YMAB in Q1 2022 and held it in 4 quarters. The position peaked at $108K in Q3 2022. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Aquatic Capital Management reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Aquatic Capital Management sold 2,520 Y-mAbs Therapeutics shares in Q1 2025, an estimated $19.7K.
  • Aquatic Capital Management first reported a position in Y-mAbs Therapeutics in Q1 2022 and held it in 4 quarters.
  • Aquatic Capital Management's Y-mAbs Therapeutics position peaked at $108K in Q3 2022.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Aquatic Capital Management's 13F filing for Q1 2025, filed 15 May 2025.